References
- Antoine MH, Mlika M. 2024 Apr 20. Interstitial lung disease [internet. In: StatPearls. StatPearls Publishing; Available from: https://www.ncbi.nlm.nih.gov/books/NBK541084/
- Zeng Q, Jiang D. Global trends of interstitial lung diseases from 1990 to 2019: an age-period-cohort study based on the global burden of disease study 2019, and projections until 2030. Front Med. 2023;10:1141372. doi: 10.3389/fmed.2023.1141372
- Chen X, Guo J, Yu D, et al. Predictors of mortality in progressive fibrosing interstitial lung diseases. Front Pharmacol. 2021;12:754851. doi: 10.3389/fphar.2021.754851
- Johannson KA, Chaudhuri N, Adegunsoye A, et al. Treatment of fibrotic interstitial lung disease: current approaches and future directions. Lancet. 2021;398(10309):1450–1460. doi: 10.1016/S0140-6736(21)01826-2
- Amati F, Stainer A, Polelli V, et al. Efficacy of pirfenidone and nintedanib in interstitial lung diseases other than idiopathic pulmonary fibrosis: a systematic review. Int J Mol Sci. 2023;24(9):7849. doi: 10.3390/ijms24097849
- Sotiropoulou V, Karampitsakos T, Katsaras M, et al. What is new in the treatment of interstitial lung diseases. Pneumon. 2023;36(2):14. doi: 10.18332/pne/161867
- Guo H, Sun J, Zhang S, et al. Progress in understanding and treating idiopathic pulmonary fibrosis: recent insights and emerging therapies. Front Pharmacol. 2023;14:1205948. doi: 10.3389/fphar.2023.1205948
- Maher TM, Nambiar AM, Wells AU. The role of precision medicine in interstitial lung disease. Eur Respir J. 2022;60(3):2102146. doi: 10.1183/13993003.02146-2021
- Finlay WH. Deposition of aerosols in the lungs: particle characteristics. J Aerosol Med Pulm Drug Deliv. 2021 Aug;34(4):213–216. doi: 10.1089/jamp.2021.29040.whf
- Sanchis J, Corrigan C, Levy ML, et al. Inhaler devices - from theory to practice. Respir med. 2013 Apr;107(4):495–502. doi: 10.1016/j.rmed.2012.12.007
- Usmani OS, Biddiscombe MF, Yang S, et al. The topical study of inhaled drug (salbutamol) delivery in idiopathic pulmonary fibrosis. Respir Res. 2018 Feb 6;19(1):25. doi: 10.1186/s12931-018-0732-0
- Wright CE, Fraser SD, Brindle K, et al. Inhaled beclomethasone/formoterol in idiopathic pulmonary fibrosis: a randomised controlled exploratory study. ERJ Open Res. 2017 Dec 14;3(4):00100–2017. doi: 10.1183/23120541.00100-2017
- Martin AR. Regional deposition: targeting. J Aerosol Med Pulm Drug Deliv. 2021 Feb;34(1):1–10. doi: 10.1089/jamp.2021.29033.am
- de Kruijf W, Ehrhardt C, Inhalation delivery of complex drugs-the next steps. Curr Opin Pharmacol. 2017 Oct;36:52–57. doi: 10.1016/j.coph.2017.07.015
- Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–1769. doi: 10.1016/S0140-6736(11)60405-4
- Khoo JK, Montgomery AB, Otto KL, et al. A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 study of aerosolized pirfenidone delivered via the PARI Investigational eFlow nebulizer in volunteers and patients with idiopathic pulmonary fibrosis. J Aerosol Med Pulm Drug Deliv. 2020 Feb;33:(1):15–20.
- Avalyn Pharma News [Internet]. c2010-2024. Avalyn presents data from its AP01 and AP02 inhaled therapeutics programs for pulmonary fibrosis. Seattle (WA): Avalyn Pharma Inc; 2023 Nov 9 [cited 2024 Apr 23]; [About 6 screens]. Available from: https://www.avalynpharma.com/avalyn-presents-data-from-its-ap01-and-ap02-inhaled-therapeutics-programs-for-pulmonary-fibrosis/
- Dempsey TM, Thao V, Moriarty JP, et al. Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States. BMC Pulm Med. 2022;22(1):18. doi: 10.1186/s12890-021-01811-0
- Humphries B, Saunders M, Cruwys S. Inhaled NXP002 attenuates LPS-induced inflammatory and fibrotic mediator production in the rat lung. Eur Respir J. 2022;60(Suppl 66):2955. doi: 10.1183/13993003.congress-2022.2955
- Avalyn Pipeline [Internet]. c2010-2024. Inhaled nintedanib. Seattle (WA): Avalyn Pharma Inc.; [cited 2024 Apr 24]; [About 1 screen] Available from: https://www.avalynpharma.com/ap03/
- Avalyn Pipeline [Internet]. c2010-2024. Inhaled nintedanib dry-powder. Seattle (WA): Avalyn Pharma Inc.; [cited 2024 Apr 24]; [About 1 screen]. Available from: https://www.avalynpharma.com/ap02-dp/
- Timaner M, Fishman-Jacob T, Pertzov B, et al. Harnessing the therapeutic power of secretomes to treat IPF. Eur Respir J. 2022;60(Suppl 66):427. doi: 10.1183/13993003.congress-2022.427
- UKRI Gateway [Internet]. c2018-2024. development of inhaled, dual EP2/4 receptor agonists for the treatment of idiopathic pulmonary fibrosis. Swindon (UK): UK Research and Innovation; 2021 Sep 1 [cited 2024 Apr 24]; [about 2 screens]. Available from: https://gtr.ukri.org/projects?ref=MR%2FV005928%2F1
- Ghanem M, Justet A, Archer G, et al. Inhaled FGF19 therapy in pulmonary fibrosis. 2023 ;207: A4708. doi:10.1164/ajrccm-conference.2023.207.135
- Pulmonary fibrosis news [internet]. c2013-2024. Novel NOX4 blockers could treat fibrosis at the source, scientists Say. Pensacola (FL): BioNews Inc. 2018 Mar 4 [cited 2024 Apr 24]; [about 2 pages] Available from: https://pulmonaryfibrosisnews.com/news/novel-nox4-blockers-could-treat-fibrosis-at-the-source-scientists-say/
- Globenewswire [Internet]. c1998-2024. VYNE Therapeutics Announces Positive Preclinical Data for inhaled formulation of VYN201 in an in vivo Model of idiopathic pulmonary fibrosis. Los Angeles (CA): Globenewswire; 2023 Apr 19 [cited 2024 Apr 24]; [about 14 pages].Available from: https://www.globenewswire.com/news-release/2023/04/19/2649968/0/en/VYNE-Therapeutics-Announces-Positive-Preclinical-Data-for-Inhaled-Formulation-of-VYN201-in-an-In-Vivo-Model-of-Idiopathic-Pulmonary-Fibrosis.html
- Diwan R, Bhatt HN, Beaven E, et al. Emerging delivery approaches for targeted pulmonary fibrosis treatment. Adv Drug Deliv Rev. 2024 Jan;204:115147. doi: 10.1016/j.addr.2023.115147
- West A, Chaudhuri N, Barczyk A, et al. Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose-response trial. Thorax. 2023 Sep;78(9):882–889. doi: 10.1136/thorax-2022-219391
- Pirfenidone inhalation - Avalyn Pharmaceuticals [internet]. Auckland: Adis International Ltd.; 2023 [cited 18 Nov 2023] Available from: https://adisinsight.springer.com/drugs/800051428
- Olitigaltin - Galecto Inc [Internet]. Auckland: Adis International Ltd.; 2023 [cited 2023 Nov 18] Available from: https://adisinsight.springer.com/drugs/800041385
- GSK 3008348 [Internet]. Auckland: Adis International Ltd.; 2023 [2023 Nov 18] Available from: https://adisinsight.springer.com/drugs/800043800
- Epstein-Shochet G, Pham S, Beck S, et al. Inhalation: a means to explore and optimize nintedanib’s pharmacokinetic/pharmacodynamic relationship. Pulm Pharmacol Ther. 2020 Aug;63:101933. doi: 10.1016/j.pupt.2020.101933
- Nintedanib inhalation - Avalyn Pharmaceuticals [internet]. Auckland: Adis International Ltd.; 2023 [cited 2023 Nov 18] Available from: https://adisinsight.springer.com/drugs/800058406
- ARO MMP7 [Internet]. Auckland: Adis International Ltd.; 2023 [cited 2023 Nov 18] Available from: https://adisinsight.springer.com/drugs/800068689
- PRS 220 [Internet]. Auckland: Adis International Ltd.; 2023 [cited 2023 Nov 18] Available from: https://adisinsight.springer.com/drugs/800064388
- Nathan SD, Behr J, Cottin V, et al. Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis. BMJ Open Respir Res. 2022 Jul;9(1):e001310. doi: 10.1136/bmjresp-2022-001310